NZ707033A - Dispersible nimorazole tablet - Google Patents

Dispersible nimorazole tablet

Info

Publication number
NZ707033A
NZ707033A NZ707033A NZ70703313A NZ707033A NZ 707033 A NZ707033 A NZ 707033A NZ 707033 A NZ707033 A NZ 707033A NZ 70703313 A NZ70703313 A NZ 70703313A NZ 707033 A NZ707033 A NZ 707033A
Authority
NZ
New Zealand
Prior art keywords
nimorazole
tablet
dispersible
dispersion
patient
Prior art date
Application number
NZ707033A
Inventor
Dumbre Nilesh Tanhaji
Bhadgale Mahesh Mohanrao
Bafna Vardhaman Chandrakant
Original Assignee
Azanta As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK201270714A external-priority patent/DK177906B1/en
Priority claimed from US13/680,216 external-priority patent/US8703188B1/en
Application filed by Azanta As filed Critical Azanta As
Publication of NZ707033A publication Critical patent/NZ707033A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention relates to a tablet comprising Nimorazole. In particular, the invention concerns a pharmaceutical composition or a tablet comprising Nimorazole or a pharmaceutically acceptable salt thereof, for dispersion in water and administration via a tube to a patient with swallowing difficulties.
NZ707033A 2012-11-19 2013-11-18 Dispersible nimorazole tablet NZ707033A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK201270714A DK177906B1 (en) 2012-11-19 2012-11-19 Dispersible tablet
US13/680,216 US8703188B1 (en) 2012-11-19 2012-11-19 Dispersible tablet
PCT/DK2013/050384 WO2014075692A1 (en) 2012-11-19 2013-11-18 Dispersible tablet

Publications (1)

Publication Number Publication Date
NZ707033A true NZ707033A (en) 2016-11-25

Family

ID=49683383

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ707033A NZ707033A (en) 2012-11-19 2013-11-18 Dispersible nimorazole tablet

Country Status (12)

Country Link
EP (1) EP2919754A1 (en)
JP (1) JP2015537013A (en)
AU (1) AU2013347264B2 (en)
BR (1) BR112015011408A2 (en)
CA (1) CA2888856A1 (en)
EA (1) EA201590732A1 (en)
MX (1) MX2015006217A (en)
NZ (1) NZ707033A (en)
RU (1) RU2015117921A (en)
TN (1) TN2015000156A1 (en)
WO (1) WO2014075692A1 (en)
ZA (1) ZA201502896B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS64308B1 (en) * 2015-01-27 2023-07-31 Janssen Pharmaceutica Nv Dispersible compositions
SI3277270T1 (en) 2015-04-01 2022-04-29 Akebia Therapeutics, Inc. Compositions and methods for treating anemia

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009537538A (en) * 2006-05-15 2009-10-29 アカドイア プハルマセウチカルス インコーポレーテッド Pimavanserin pharmaceutical formulation
JP2008081448A (en) * 2006-09-28 2008-04-10 Kowa Pharmaceutical Co Ltd Bitterness masking rapid release particle of zolpidem tartrate
US20080131467A1 (en) * 2006-11-30 2008-06-05 Dennis Nelson Film-coated solid dosage form
US9278063B2 (en) * 2009-12-11 2016-03-08 Sumitomo Dainippon Pharma Co., Ltd. Press-coated orally-disintegrating tablets
KR20130100892A (en) * 2010-04-14 2013-09-12 유파마 피티와이 엘티디 Radiation sensitiser compositions

Also Published As

Publication number Publication date
ZA201502896B (en) 2016-11-30
TN2015000156A1 (en) 2016-10-03
EP2919754A1 (en) 2015-09-23
WO2014075692A1 (en) 2014-05-22
JP2015537013A (en) 2015-12-24
AU2013347264B2 (en) 2016-10-27
AU2013347264A1 (en) 2015-05-07
CA2888856A1 (en) 2014-05-22
EA201590732A1 (en) 2016-01-29
BR112015011408A2 (en) 2017-07-11
RU2015117921A (en) 2017-01-10
MX2015006217A (en) 2015-11-16

Similar Documents

Publication Publication Date Title
IL223783B (en) Substituted 1-indole compound for use in the treatment of a disease or condition, a pharmaceutical composition comprising the compound and use of the compound for the preparation of a medicament
MX351584B (en) Aqueous pharmaceutical formulation of tapentadol for oral administration.
EP3904502A3 (en) Compositions and methods
SG10201810985XA (en) Tofacitinib oral sustained release dosage forms
MX366090B (en) Pharmaceutical combination for use in inducing weight loss in diabetes type 2 patients or/and for preventing weight gain in diabetes type 2 patients.
PH12015500823A1 (en) Modified release formulations for oprozomib
MX347105B (en) Pharmaceutical compositions comprising hydromorphone and naloxone.
MX344846B (en) Combination of active loaded granules with additional actives.
WO2014114255A3 (en) Positioning, quick-release bioadhesion agent and use
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX363389B (en) Pharmaceutical composition comprising amorphous ivabradine.
EP3318879A4 (en) Gpc3-targeted therapeutic agent administered to patient in whom gpc3-targetd therapeutic ag
PH12015501377A1 (en) Solid unit with high fexofenadine content and process for the preparation thereof
IN2015DN02999A (en)
TN2015000156A1 (en) Dispersible tablet
MX2013010947A (en) Gallium complexes, pharmaceutical compositions and methods of use.
MX2014006201A (en) Imatinib solid dosage forms reconstituted just before use.
MX2016011706A (en) Progesterone formulations.
SA515360445B1 (en) Dispersible tablet
DK201270714A (en) Dispersible tablet
PH12014501822A1 (en) Oral formulation comprising lansoprazole and the preparation method thereof
PH12015500070B1 (en) Pediatric oral liquid compositions containing nepadutant
UA105513C2 (en) Glucosamine prolonged release dosage form
UA56353U (en) method for restoration of tear-nasal canal in children with administration of drug
UA88640U (en) Use of combined drug thiocetam for correction of inflammations in oral mucosa

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 NOV 2018 BY COMPUTER PACKAGES INC

Effective date: 20171031

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 NOV 2019 BY COMPUTER PACKAGES INC

Effective date: 20181031

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 NOV 2020 BY COMPUTER PACKAGES INC

Effective date: 20191031

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 NOV 2021 BY COMPUTER PACKAGES INC

Effective date: 20201031

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 NOV 2022 BY CPA GLOBAL

Effective date: 20211008

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 NOV 2023 BY CPA GLOBAL

Effective date: 20221007

ASS Change of ownership

Owner name: INPHENA APS, DK

Effective date: 20230217

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 NOV 2024 BY COMPUTER PACKAGES INC

Effective date: 20231030